VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ARGXargenx SE
$887.18$54.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksARGXBalance Sheet

argenx SE (ARGX) Balance Sheet

15Y historyFree accessUpdated daily

The firm maintains a fortress-like balance sheet with a current ratio of 5.23 and a minimal debt-to-equity ratio of 0.01, supporting long-term clinical development.

ARGX Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Total Current Assets6.9B4.88B4.12B2.77B2.54B2.06B1.54B654.82M440.06M107.06M48.26M69.77M33.73M22.48M31.57M
Cash & Short-Term Investments4.44B3.38B3.18B2.19B2.34B2B1.5B645.81M431.62M101.73M46.28M55.97M32.06M21.8M30.52M
Cash Only3.49B1.5B2.05B800.74M1.33B1.22B372.16M321.48M228.98M94.55M38.83M32.18M31.37M20.41M30.52M
Short-Term Investments948.75M1.88B1.13B1.39B1B779.65M1.13B324.33M202.64M7.18M7.45M28.93M690.44K1.39M0
Accounts Receivable1.66B909.1M499.27M277.27M38.22M7.44M36.17M4.36M845K1.12M719K1.59M1.52M568.68K986.33K
Days Sales Outstanding145.62151.5148.6246.3928.0565.85168.2664.717.0626.3735.02127.47149.9795.08246.92
Inventory473.53M407.23M310.55M228.35M109.08M25.2M000000000
Days Inventory Outstanding383.52653.97961.942.83K-----------
Other Current Assets00000002.31M3.85M826.64K637K01.38K2.65K1.3K
Total Non-Current Assets1.78B1.32B418.72M360.06M307.3M222.41M67.54M6.88M4.92M4.18M2M1.13M809.19K450.97K371.98K
Property, Plant & Equipment48.25M43.52M22.68M16.23M15.84M11.58M9.18M942.58K811K805.6K272.23K166K165.7K231.44K356.43K
Fixed Asset Turnover86.09x50.33x54.08x25.30x31.39x3.56x8.55x26.07x53.87x19.21x27.52x27.51x22.31x9.43x4.09x
Goodwill000000000000000
Intangible Assets272.1M181.44M125.23M174.9M171.68M167.34M45.12M64.06K15.6K17.88K7.65K8.51K0015.55K
Long-Term Investments89.59M49.7M47.16M40.48M53.17M6.31M2.92M1.14K1.2K1.05K1.09K1K1.38K1.32K0
Other Non-Current Assets77.8M120.46M126.45M49.23M34.42M22.14M10.33M5.87M4.1M3.36M1.71M1.17M642.11K218.21K0
Total Assets8.68B6.2B4.54B3.13B2.85B2.28B1.61B661.7M444.98M111.24M50.25M58.51M34.54M22.93M31.94M
Asset Turnover0.48x0.35x0.27x0.13x0.17x0.02x0.05x0.04x0.10x0.14x0.15x0.08x0.11x0.10x0.05x
Asset Growth %39.99%36.55%44.93%9.96%25.04%41.56%143.35%48.7%300.01%121.38%-14.12%69.4%50.63%-28.21%-
Total Current Liabilities1.32B669.92M422.99M302.28M301.24M328.49M179.7M45.82M29.41M34M9.43M10.25M4.57M6.28M4.04M
Accounts Payable1.27B342.23M245.56M188.72M208.85M206.32M10.51M6.87M5.28M4.63M2.94M4.08M2.89M2.5M887.93K
Days Payables Outstanding1.03K549.58760.632.34K--------1.03K--
Short-Term Debt10.83M6.53M4.65M3.42M3.51M3.48M2.22M0000002.23M2.2M
Deferred Revenue (Current)0000046.33M136.28M23.21M16.95M37.27M4.5M4.18M628.35K568.23K0
Other Current Liabilities-212.34M156.95M73.35M22.62M828K0000329.08K449.73K203.29K73.03K106.79K190.83K
Current Ratio5.23x7.29x9.75x9.18x8.44x6.26x8.58x14.29x14.96x3.15x5.12x6.81x7.38x3.58x7.81x
Quick Ratio4.87x6.68x9.01x8.42x8.08x6.19x8.58x14.29x14.96x3.15x5.12x6.81x7.38x3.58x7.81x
Cash Conversion Cycle-497.14255.89349.92737.91-----------
Total Non-Current Liabilities39.42M34.32M21.96M18.29M14.81M276.86M250.11M8.01K1.75M10.59M00-1.38K00
Long-Term Debt36.33M00000000000000
Capital Lease Obligations36.33M32.52M15.35M9.01M7.96M6.18M5.1M00000000
Deferred Tax Liabilities005.16M8.41M6.44M1.49M000000000
Other Non-Current Liabilities-33.23M1.8M1.45M870K417K156K72K8.01K1.75M10.59M00-1.38K00
Total Liabilities1.36B704.24M444.95M320.56M316.05M605.36M429.81M45.83M31.16M44.59M9.43M10.25M4.57M6.28M4.04M
Total Debt83.49M39.05M20M12.43M11.46M9.66M7.32M00000000
Net Debt-3.41B-1.46B-2.03B-788.31M-1.32B-1.2B-364.84M-321.48M-228.98M-94.55M-38.83M-39.13M-31.37M-20.41M-30.52M
Debt / Equity0.01x0.01x0.00x0.00x0.00x0.01x0.01x--------
Debt / EBITDA0.08x--------------
Net Debt / EBITDA-3.15x--------------
Interest Coverage314.23x39.50x-335.83x-331.56x-363.73x-1498.68x-1264.60x-----3436.95x-1531.96x-4848.02x-3464.51x
Total Equity7.32B5.5B4.1B2.81B2.53B1.67B1.18B615.87M413.81M66.65M40.76M60.9M29.97M16.65M27.9M
Equity Growth %33.19%34.19%45.63%11.03%51.38%41.82%91.66%48.83%520.87%63.54%-33.08%103.19%79.99%-40.31%-
Book Value per Share110.9184.3671.6751.7449.6236.8730.5717.1216.813.542.593.881.911.061.78
Total Shareholders' Equity7.32B5.5B4.1B2.81B2.53B1.67B1.18B615.87M413.81M66.65M40.76M60.9M29.97M16.65M27.9M
Common Stock7.35M6.98M6.39M6.64M6.23M5.74M5.21M4.12M3.86M2.12M1.73M1.91M643.49K448.33K439.38K
Retained Earnings-279.77M-1.57B-2.4B-2.11B-1.4B-991.93M-383.48M-194.01M-120.65M-76.24M-55.89M-43.54M-35.2M-25.6M-12.52M
Treasury Stock000000000000000
Accumulated OCI73.59M66.71M72.07M71.72M465.41M321.21M53.04M35.4M14.11M7.88M5.08M2.89M1.97M1.56M540.47K
Minority Interest000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetFortress
Cash FlowImproving
Top Statement Risk

Indication expansion clinical failure

Capital Base Expansion Supports Maturity

According to recent financial statements, argenx has significantly bolstered its total asset base to $8.7 billion by 2025Q4, reflecting a strategic shift from a capital-consuming R&D entity to a commercial-stage powerhouse with the financial depth required to sustain global clinical development and market expansion efforts.

The expansion of the balance sheet appears to be driven by the successful commercialization of its primary franchise, which has allowed for a substantial accumulation of cash reserves. This trajectory suggests that the company is moving toward a self-sustaining model where internal capital generation reduces the necessity for dilutive equity financing.

Robust Liquidity Buffers Operational Volatility

As reported in quarterly filings, argenx maintains a strong liquidity position with a current ratio of 5.23 in 2025Q4, providing a substantial buffer against potential shocks in the commercial launch cycle or unforeseen delays in the pipeline-in-a-product clinical development strategy for its core therapeutic assets.

The high current ratio indicates that the company is well-positioned to meet its short-term obligations without relying on external credit markets. Investors should monitor whether this liquidity remains elevated as the company potentially increases its investment in secondary indications or pursues inorganic growth opportunities.

Equity Quality Improving Through Profitability

Based on reported figures, the company's equity base has grown to $7.3 billion by 2025Q4, signaling a transition toward improved earnings quality as the firm begins to narrow its accumulated deficit, which previously reflected years of heavy, non-profitable investment in the SIMPLE Antibody platform.

The reduction in the accumulated deficit suggests that the core business is finally generating the returns necessary to offset historical R&D expenditures. This improvement in equity quality may indicate a lower risk profile for long-term shareholders as the company moves past its most capital-intensive development phase.

Goodwill Risk and Asset Composition

As indicated by the latest balance sheet data, argenx holds $272.1 million in goodwill as of 2025Q4, which warrants further investigation into the underlying valuation of past acquisitions and whether potential clinical failures in secondary indications could trigger future impairment charges that impact reported book value.

While the current goodwill figure remains a small fraction of total assets, the reliance on a single-product platform makes the company sensitive to any clinical setbacks that could diminish the perceived value of its intangible assets. Investors should remain cautious about the potential for non-cash write-downs if the pipeline-in-a-product strategy faces further regulatory or clinical hurdles.

ARGX — Frequently Asked Questions

Quick answers to the most common questions about buying ARGX stock.

What are the total assets of argenx SE (ARGX)?

As of 2025, argenx SE (ARGX) had total assets of $8.68B including $6.90B in current assets.

How much debt does argenx SE (ARGX) have?

argenx SE (ARGX) carries total debt of $83.5M, offset by $4.44B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of argenx SE?

argenx SE (ARGX) has total shareholders' equity (book value) of $7.32B ($110.91 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is argenx SE's current ratio and liquidity?

argenx SE (ARGX) reported a current ratio of 5.23x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.